This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Frank Beurskens, PhD
Principal Scientist at Genmab


Dr. Frank Beurskens works at Genmab since 2002. He is interested in how antibodies work and how they can boost the immune system of patients. He discovered that antibodies act together as a team after binding to the target at the cell surface. This knowledge lead to the discovery of the HexaBody® and HexElect® technologies, which he co-developed. He currently leads Genmab’s Antibody Format Translation efforts, aimed at translating novel therapeutic antibody platform technologies into potential immune-therapeutics.

Agenda Sessions

  • Equilibriums in Antibody Hexamerization: The Unpredicted Path to Product Design

    On Demand
  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #6: MODIFYING FC INTERACTIONS TO ENHANCE ANTIBODY THERAPIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #6 in the Watch On-Demand Sessions Tab prior to this session